<DOC>
	<DOCNO>NCT01212276</DOCNO>
	<brief_summary>The purpose study evaluate whether therapy MORAb-028 safe , effective , determine appropriate dose MORAb-028 treatment metastatic melanoma .</brief_summary>
	<brief_title>A Safety MORAb-028 Dose Determination Study Subjects With Metastatic Melanoma</brief_title>
	<detailed_description>Melanoma serious form skin cancer . If untreated , melanoma spread beyond original affected tissue invade distant tissue organ . Treatment metastatic melanoma include medical treatment ( chemotherapy immunotherapy ) , surgery , radiation therapy . MORAb-028 recombinant human immunoglobulin M ( IgM ) monoclonal antibody recognize cell surface diacyl ganglioside name disialoganglioside ( GD2 ) . GD2 overexpressed tumor neuro-ectodermal origin melanoma , neuroblastomas , small-cell lung carcinoma , many sarcoma , absent normal tissue . GD2 expression demonstrate human melanoma small cell lung cancer thin layer chromatography radiolabeled anti-GD2 antibody detection . It hypothesize one mode action MORAb-028 complement-dependent cytotoxicity . Complement-dependent cytotoxicity mechanism kill tumor cell antibody bound target cell surface fixes complement , result assembly complement membrane attack complex punch hole target cell membrane result subsequent cell lysis . IgMs strongly bind C1Q robustly activate complement-dependent cytotoxicity . MORAb-028 develop potential therapy GD2-positive tumor .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Measurable metastatic melanoma fail standard therapy Males females great equal 18 year age Life expectancy great equal 3 month Significant cardiovascular impairment Clinically significant illness , medical condition , surgical history , laboratory abnormality could affect safety subject negatively impact study result Chemotherapy , radiotherapy , immunotherapy within 3 week prior administration MORAb028</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>